- Home
- FATE vs LUNG Comparison
FATE vs LUNG Comparison
Compare FATE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- LUNG
- Stock Information
- Founded
- FATE 2007
- LUNG 1995
- Country
- FATE United States
- LUNG United States
- Employees
- FATE N/A
- LUNG N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- FATE Health Care
- LUNG Health Care
- Exchange
- FATE Nasdaq
- LUNG Nasdaq
- Market Cap
- FATE 130.7M
- LUNG 106.3M
- IPO Year
- FATE 2013
- LUNG 2020
- Fundamental
- Price
- FATE $1.07
- LUNG $1.61
- Analyst Decision
- FATE Hold
- LUNG Buy
- Analyst Count
- FATE 7
- LUNG 7
- Target Price
- FATE $3.83
- LUNG $7.66
- AVG Volume (30 Days)
- FATE 1.4M
- LUNG 743.5K
- Earning Date
- FATE 08-12-2025
- LUNG 07-30-2025
- Dividend Yield
- FATE N/A
- LUNG N/A
- EPS Growth
- FATE N/A
- LUNG N/A
- EPS
- FATE N/A
- LUNG N/A
- Revenue
- FATE $13,335,000.00
- LUNG $90,549,000.00
- Revenue This Year
- FATE N/A
- LUNG $17.92
- Revenue Next Year
- FATE N/A
- LUNG $18.56
- P/E Ratio
- FATE N/A
- LUNG N/A
- Revenue Growth
- FATE 105.85
- LUNG 18.24
- 52 Week Low
- FATE $0.66
- LUNG $1.59
- 52 Week High
- FATE $5.49
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- FATE 40.63
- LUNG 28.06
- Support Level
- FATE $1.19
- LUNG $3.03
- Resistance Level
- FATE $1.35
- LUNG $3.39
- Average True Range (ATR)
- FATE 0.08
- LUNG 0.33
- MACD
- FATE -0.01
- LUNG -0.13
- Stochastic Oscillator
- FATE 3.45
- LUNG 0.87
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.